Carbonic Anhydrase XI (CA XI) is part of the carbonic anhydrase family, enzymes critical for maintaining acid-base balance in various tissues by catalyzing the reversible hydration of carbon dioxide to bicarbonate and protons. While the specific physiological role of CA XI remains less defined compared to other members of the carbonic anhydrase family, it is understood to contribute to pH regulation, ion transport, and CO2 removal from tissues. Given its expression in the brain and other tissues, CA XI might play roles in neuronal ion transport and the maintenance of the acid-base balance in the central nervous system, which are crucial for normal neuronal function and signaling. The precise functions and expression patterns of CA XI suggest its involvement in finely tuned physiological processes, indicating that its activity is critical for maintaining homeostasis within specific cellular environments.
The inhibition of CA XI, as with other carbonic anhydrases, can be achieved through various mechanisms that interfere with its catalytic activity. One common approach involves the use of small molecule inhibitors that bind to the active site of the enzyme, preventing the coordination of water molecules necessary for the hydration of carbon dioxide. These inhibitors typically mimic the structure of the substrate (CO2) or the reaction intermediate (HCO3-) and can bind to the zinc ion at the active site, which is crucial for the enzyme's catalytic activity. Such inhibition disrupts the enzyme's ability to maintain pH balance and ion transport, affecting the physiological processes that rely on efficient CO2 removal and bicarbonate production. The development of specific inhibitors for CA XI requires a detailed understanding of its active site architecture and the dynamics of its interaction with CO2, water, and bicarbonate. The selective inhibition of CA XI over other carbonic anhydrase isoforms necessitates precise molecular targeting, given the widespread and critical nature of carbonic anhydrase activity in various tissues. This specificity is essential to avoid disrupting the broader physiological functions mediated by the carbonic anhydrase family.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Blocks L-type calcium channels in cardiac muscle cells, reducing calcium influx and blocking muscle contraction, thereby lowering blood pressure and reducing cardiac workload. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Inhibits L-type calcium channels in cardiac and smooth muscle cells, leading to decreased heart rate, reduced contractility, and vasodilation, resulting in lower blood pressure. | ||||||
Diltiazem | 42399-41-7 | sc-204726 sc-204726A | 1 g 5 g | $209.00 $464.00 | 4 | |
Blocks calcium influx through L-type calcium channels in cardiac and smooth muscle cells, reducing heart rate and myocardial contractility, leading to decreased blood pressure. | ||||||
Amlodipine | 88150-42-9 | sc-200195 sc-200195A | 100 mg 1 g | $74.00 $166.00 | 2 | |
Selectively inhibits L-type calcium channels in vascular smooth muscle, causing vasodilation and lowering blood pressure. | ||||||
Felodipine | 72509-76-3 | sc-201483 sc-201483A | 10 mg 50 mg | $91.00 $222.00 | 1 | |
Blocks calcium influx through L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure. | ||||||
Isradipine | 75695-93-1 | sc-201467 sc-201467A | 10 mg 50 mg | $88.00 $324.00 | 1 | |
Inhibits L-type calcium channels in vascular smooth muscle, resulting in vasodilation and a reduction in blood pressure. | ||||||
Nimodipine | 66085-59-4 | sc-201464 sc-201464A | 100 mg 1 g | $61.00 $307.00 | 2 | |
Inhibits L-type calcium channels in cerebral arteries,blocking calcium influx, and improving blood flow in the brain, used for cerebral vasospasm. | ||||||
Manidipine | 89226-50-6 | sc-211774 | 10 mg | $278.00 | ||
Blocks L-type calcium channels in vascular smooth muscle, leading to vasodilation and lowering blood pressure. | ||||||
Cilnidipine | 132203-70-4 | sc-201485 sc-201485A sc-201485B | 10 mg 50 mg 1 g | $74.00 $284.00 $450.00 | 1 | |
Inhibits L-type calcium channels in vascular smooth muscle, resulting in vasodilation and reduced blood pressure. | ||||||
trans Lacidipine | 103890-78-4 | sc-213066 | 10 mg | $153.00 | ||
Selectively blocks L-type calcium channels in vascular smooth muscle, causing vasodilation and lowering blood pressure. | ||||||